Pomalidomide + low-dose dexamethasone should be considered a standard of care in patients with refractory or relapsed and refractory multiple myeloma regardless of prior treatment.

Phase III trial MM-003
455 patients with refractory or relapsed and refractory multiple myeloma after failure of bortezomib and lenalidomide treatment.

Investigational treatment:

- pomalidomide + low-dose dexamethasone
- high-dose dexamethasone

Progression-free survival
- 4.0 months (HR=0.50, p<0.001*)
- 1.9 months

Overall-free survival
- 13.1 months (HR=0.72, p=0.009*)
- 8.1 months

*these benefits are generally maintained regardless of the number or type of prior therapies

San Miguel et al., Haematologica, 2015